Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Return on Capital Employed of 14.75% for Q1 2026, up 8274.0% year-over-year from 0.18% in Q1 2025, and up 715.65% quarter-over-quarter from 1.81% in Q4 2025.
Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Return on Capital Employed for 13 consecutive years, with 14.75% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 8274.0% year-over-year to 14.75%; the TTM figure through Mar 2026 stood at 14.75% (up 8274.0% YoY), while the FY2025 annual figure was 2.44%, up 8160.0% from the prior year.
- Return on Capital Employed advanced to 14.75% in Q1 2026 per SLNO's latest filing, from 1.81% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 14.75% in Q1 2026 and bottomed at 181.25% in Q3 2023.
- Historically, Return on Capital Employed has averaged 73.03% across 5 years, with a median of 63.6% in 2024.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 10255 bps — and 2024, when it soared 14405 bps.
- Soleno Therapeutics' Return on Capital Employed stood at 111.27% in 2022, then soared by 66 bps to 37.41% in 2023, then sank by 70 bps to 63.6% in 2024, then jumped by 103 bps to 1.81% in 2025, then soared by 716 bps to 14.75% in 2026.
- Business Quant data shows SLNO's Return on Capital Employed at 14.75% in Q1 2026, 1.81% in Q4 2025, and 20.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 14.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.75% |
| Dec 31, 2025 | 1.81% |
| Sep 30, 2025 | -20.63% |
| Jun 30, 2025 | -62.97% |
| Mar 31, 2025 | -67.99% |
| Dec 31, 2024 | -63.60% |
| Sep 30, 2024 | -49.91% |
| Jun 30, 2024 | -31.95% |
| Mar 31, 2024 | -34.96% |
| Dec 31, 2023 | -37.41% |
| Sep 30, 2023 | -181.25% |
| Jun 30, 2023 | -176.00% |
| Mar 31, 2023 | -177.60% |
| Dec 31, 2022 | -111.27% |
| Sep 30, 2022 | -80.46% |
| Jun 30, 2022 | -73.45% |
| Mar 31, 2022 | -88.68% |
| Dec 31, 2021 | -101.53% |
| Sep 30, 2021 | -99.60% |
| Jun 30, 2021 | -81.24% |